CDK4/6-IN-9

• UNSPSC Description:

  CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC50 of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk4-6-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN1C=C(C2=NC(NC3=NC=C(CN4CCNCC4)C=C3)=NC=C2F)C5=CC=CN=C51

• Molecular Weight:

  418.47

• References & Citations:

  [1]Kai Yuan, et al. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem. 2022 Jan 15;228:114024.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2688098-02-2